<DOC>
	<DOCNO>NCT01702571</DOCNO>
	<brief_summary>This two-cohort , open-label , multicenter study ass safety , efficacy tolerability trastuzumab emtansine participant HER2-positive locally advanced breast cancer ( LABC ) metastatic breast cancer ( mBC ) receive prior anti-HER2 chemotherapy-based treatment . Participants Cohort 1 drawn general participant population ; Cohort 2 include Asian participant .</brief_summary>
	<brief_title>A Study Trastuzumab Emtansine Participants With Human Epidermal Growth Factor Receptor 2 ( HER2 ) Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>HER2positive disease determine locally Histologically cytologically confirm invasive breast cancer Prior treatment breast cancer adjuvant , unresectable , locally advanced metastatic setting must include chemotherapy , alone combination another agent , antiHER2 agent , alone combination another agent Documented progression incurable , unresectable , LABC , mBC , define investigator : progression must occur recent treatment LABC/mBC within 6 month complete adjuvant therapy Measurable and/or nonmeasurable disease Left ventricular ejection fraction ( LVEF ) &gt; /=50 % either echocardiogram ( ECHO ) multiplegated acquisition scan ( MUGA ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0,1 2 Adequate organ function Use highly effective contraception define protocol History treatment trastuzumab emtansine Prior enrollment clinical study contain trastuzumab emtansine regardless receive trastuzumab emtansine Peripheral neuropathy Grade &gt; /= 3 per National Cancer Institute ( NCI ) common terminology criterion adverse event ( CTCAE ) v 4.0 History malignancy within previous 5 year , except appropriately treat carcinoma situ cervix , nonmelanoma skin carcinoma , Stage 1 uterine cancer , synchronous previously diagnose HER2positive breast cancer History receive anticancer drug/biologic investigational treatment within 21 day prior first study treatment except hormone therapy , give 7 day prior first study treatment ; recovery treatmentrelated toxicity consistent eligibility criterion History exposure cumulative dos anthracyclines History radiation therapy within 14 day first study treatment . The participant must recover result acute toxicity ( Grade &lt; /=1 ) prior first study treatment . Metastatic central nervous system ( CNS ) disease Brain metastases symptomatic History decrease LVEF le ( &lt; ) 40 % symptomatic congestive heart failure ( CHF ) previous trastuzumab treatment History symptomatic CHF ( New York Heart Association [ NYHA ] Classes IIIV ) serious cardiac arrhythmia require treatment History myocardial infarction unstable angina within 6 month first study treatment Current dyspnea rest due complication advance malignancy requirement continuous oxygen therapy Current severe , uncontrolled systemic disease ( clinically significant cardiovascular , pulmonary , metabolic disease ) Pregnancy lactation Currently know active infection human immunodeficiency virus ( HIV ) , hepatitis B virus , hepatitis C virus History intolerance ( Grade 34 infusion reaction ) hypersensitivity trastuzumab murine protein component product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>